))
DME/Retina Edition: Top Headlines for Week of April 8, 2024
Manage episode 411942305 series 3560281
İçerik Healio tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Healio veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here:
PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes
Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases
VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab
VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Early safety, efficacy results positive for Restoret in DME, wet AMD
References:
Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
115 bölüm
Paylaş
